Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ELTX
STRONG SELLElicio Therapeutics, Inc. · Healthcare · United States · $79M · Avg Vol: $10M/d
COMPANY DESCRIPTION
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, utilizing its proprietary AMP (Amphiphile) technology platform. The company's lead product candidate, ELI-002, is an 'amph-modified' vaccine designed to boost immune responses to KRAS-mutated cancers. Elicio's competitive edge lies in its innovative approach to enhance cancer immunotherapies by precisely targeting lymph nodes to activate immune cells.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.90 | -2.54 | -1.78 | -2.58 | — | -2.31 | -2.07 | -2.43 | — |
| Shares | 26.3M | 26.3M | 26.3M | 17.8M | -32.2% | — | — | — | — |
| Debt | 7.5M | 6.9M | 26.0M | 14.5M | 24.7% | 14.3M | — | — | — |
| Equity | -102.1M | 11.4M | -11.3M | 1.6M | -62.1% | — | — | — | — |
| Op CF | -22.2M | -32.7M | -37.1M | -37.0M | — | -38.5M | — | — | — |
| Inv CF | -0.7M | -32.0K | -84.0K | -16.0K | — | — | — | — | — |
| Fin CF | 21.2M | 38.6M | 42.3M | 36.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ELTX | Elicio Therapeutics, Inc.(you) | $79M | 3 | STRONG SELL |
| INO | Inovio Pharmaceuticals, Inc. | $80M | 0 | STRONG SELL |
| EXOZ | eXoZymes, Inc. | $73M | 0 | STRONG SELL |
| NTHI | NeOnc Technologies Holdings, Inc. | $89M | 1 | STRONG SELL |
| RNTX | Rein Therapeutics Inc. | $68M | 2 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $92M | 4 | STRONG SELL |
| CRDF | Cardiff Oncology, Inc. | $64M | 2 | STRONG SELL |
| ESLA | Estrella Immunopharma, Inc. | $62M | 2 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $82M | 7 | STRONG SELL |
| 2257.HK | Sirnaomics Ltd. | $64M | 1 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%